Results 241 to 250 of about 62,751 (282)
Some of the next articles are maybe not open access.
Proton pump inhibitors and osteoporosis
Current Opinion in Rheumatology, 2016Purpose of review The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and ...
Andersen, Bjarne Nesgaard +2 more
openaire +3 more sources
Pharmacogenomics of proton pump inhibitors
Pharmacogenomics, 2004Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Takahisa, Furuta +4 more
openaire +2 more sources
Hypomagnesemia and proton-pump inhibitors
Expert Opinion on Drug Safety, 2013Proton pump inhibitors (PPIs) have been linked to clinically symptomatic hypomagnesemia.We searched Medline database in all languages using 'proton-pump inhibitors, magnesium, hypomagnesemia and hypomagnesemic hypoparathyroidism' as search terms and other articles were identified through searches of the files of the authors and reference lists from ...
Giuseppe, Famularo +2 more
openaire +2 more sources
Esomeprazole: a proton pump inhibitor
Expert Review of Gastroenterology & Hepatology, 2009Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001.
Ravi, Vachhani +2 more
openaire +2 more sources
Proton Pump Inhibitors for Dyspepsia
Digestive Diseases, 2008Proton pump inhibitors are widely used in many upper gastrointestinal disorders. Dyspepsia is a common problem in primary care and endoscopy is neither feasible nor affordable in the majority of patients. <i>Helicobacter pylori</i> eradication has been shown to be effective, but with the declining prevalence of <i>H.
openaire +2 more sources
Overuse of proton pump inhibitors
Journal of Clinical Pharmacy and Therapeutics, 2000There have been concerns raised about the potential adverse effects of proton pump inhibitors, especially with long-term use. In particular, their potent action can suppress the features and delay the diagnosis of gastric cancer, while prolonged exposure may hasten the development of gastric carcinoids.To examine the use of proton pump inhibitors in ...
M, Naunton, G M, Peterson, M D, Bleasel
openaire +2 more sources
Lansoprazole: A Proton Pump Inhibitor
Annals of Pharmacotherapy, 1996OBJECTIVE: To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
openaire +2 more sources
An Overview of Proton Pump Inhibitors
Gastroenterology Nursing, 2003Proton pump inhibitors are the standard of treatment for acid-related disorders. These disorders include gastroesophageal reflux disease and its complications (i.e., erosive esophagitis and Barrett's esophagus), peptic ulcer disease, Zollinger-Ellison syndrome, and idiopathic hypersecretion.
openaire +2 more sources
Deprescribing Proton Pump Inhibitors
JAMA Internal Medicine, 2020Jacob E, Kurlander +2 more
openaire +2 more sources